NOWDiagnostics develops and manufactures OTC and point-of-care diagnostic tests using a patented platform that enables virtually any immunological assay to be performed in one step with a small amount of capillary blood, yielding results in minutes. The company’s platform also includes saliva and plasma test technologies to enable next-generation rapid testing at home without a blood draw or throat swab. NOWDx’s First To Know® Syphilis OTC test is undergoing De Novo review by the U.S. FDA and could become the first rapid at-home syphilis test in the U.S. The company reports more than 30 diagnostic tests in its clinical research pipeline and maintains product lines including First To Know® and ADEXUSDx® available worldwide. NOWDx holds over 75 patents issued and pending. The company says it will commercialize at-home tests, continue developing diagnostic innovations, expand its test pipeline, and support strategic hiring initiatives.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2024